Having trouble accessing articles? Reset your cache.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/25 cls
Affymax Inc. (NASDAQ:AFFY) MLV Ed Arce Price target Buy 8% $14.07
Arce raised his target to $21 from $12 after Affymax and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) launched once-monthly Omontys peginesatide in the U.S. to treat anemia in chronic kidney disease (CKD) patients who are on dialysis (see BioCentury, April 30). He believes the net overall cost of Omontys will be lower than anemia drug Epogen epoetin

Read the full 955 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE